A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Vapendavir (Primary)
- Indications Rhinovirus infections
- Focus Therapeutic Use
- Sponsors Altesa Biosciences
Most Recent Events
- 30 Sep 2025 Status changed from active, no longer recruiting to completed.
- 28 Sep 2025 According to Altesa BioSciences media release, Altesa's rhinovirus challenge study co-led by Professor Sebastian Johnston and Dr Michael Edwards. More detailed results from Altesa's Challenge Study will be submitted for publication in a peer-reviewed journal.
- 28 Sep 2025 According to Altesa BioSciences media release, data from this study were presented in a late breaker session at the European Respiratory Society (ERS) Congress 2025 meeting.